Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725931 | 0.82 | PARP15 (0.44) | PARP15NPSR1TAS1R3TAS1R1FURIN | |
| SCHEMBL17018686 | 0.78 | GRM5 (0.51) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL17680606 | 0.78 | NPSR1 (0.59) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL5520763 | 0.75 | HDAC1 (0.50) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL16799700 | 0.75 | PDE5A (0.47) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL16799699 | 0.75 | PDE5A (0.47) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL2623649 | 0.73 | ATM (0.51) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL1926964 | 0.73 | MTOR (0.52) | MTORMYCMAXHDAC1HDAC2 | |
| SCHEMBL2293623 | 0.72 | ALDH1A1 (0.63) | MTORHDAC1HDAC2GRM5TP53BP1 | |
| SCHEMBL2290042 | 0.72 | HDAC8 (0.63) | MTORHDAC1HDAC2GRM5TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130052132-A1 | Method for Producing Radioactively Labeled Polypeptide | ARKRAY, INC. (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052132-A1 | Method for Producing Radioactively Labeled Polypeptide | XPNPEP2, ARGLU1, XPNPEP1 | MTOR 3995/4885MYC 2853/4885MAX 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.